Author:Qingfeng Pharmaceutical Group
Posted Time:2023-12-04 00:00
On November 30, 2023, the Shanghai Cooperation Organization Traditional Medicine Forum kicked off in the Traditional Chinese Medicine Science and Technology Innovation City in Nanchang, China. At the invitation of the forum organizers, Qingfeng Pharmaceutical set up an exhibition booth in the Jiangxi Pavilion, where the company highlighted its major innovations, including Aurantii Fructus Immaturus Total Flavonoids tablets.
The forum was jointly organized by the Shanghai Cooperation Organization (SCO) Neighborly Friendship and Cooperation Committee, the National Administration of Traditional Chinese Medicine, and the Jiangxi Provincial People's Government. The theme of "Inherit Innovation, Unite and Collaborate, Promote High-Quality Development of the Traditional Medicine Industry," aimed to foster exchanges and cooperation between SCO member countries and promote the high-quality development of traditional medicine industries worldwide.
Yin Hong, Secretary of the Jiangxi Provincial Party Committee and Chairman of the Provincial People's Congress Standing Committee, attended and delivered the welcome address, while Ye Jianchun, Deputy Secretary of the Provincial Party Committee and Governor of Jiangxi, hosted the opening ceremony. Over 500 domestic and international government officials and industry representatives from countries such as Russia, Myanmar, Nepal, Armenia, Cambodia, Turkey, and Sri Lanka gathered to discuss the high-quality development of Traditional Chinese Medicine (TCM) and the traditional medicine industries of various countries.
During the opening ceremony, Dr. Daikai Wen, Myanmar's Minister of Health and Sports, introduced several initiatives aimed at protecting intellectual property related to traditional medicine innovation. Dr. Rahman Shah, Deputy Minister of Health in Pakistan, shared his experience using traditional herbal medicine to treat digestive diseases, especially for symptoms such as abdominal pain, constipation, and indigestion, to complement Western medicine. Gajur Real, Political Advisor to Nepal's Prime Minister, expressed his recognition and hopes for the current extensive dialogue between traditional and modern medicine initiated by China.
To showcase the innovative developments in the traditional medicine industries of SCO member countries in recent years, and to create a platform for exchange and cooperation, the conference set up a special Traditional Medicine Industry Exhibition Hall. At the invitation of the forum organizers, Qingfeng Pharmaceutical Group set up a booth at the Jiangxi Pavilion, highlighting key innovations, including Aurantii Fructus Immaturus Total Flavonoids tablets.
Innovation in Traditional Chinese Medicine (TCM) is a critical step forward in the advancement of China’s medicine industry, but it comes with significant development challenges. Compared to new chemical and biological drugs, innovative TCM must meet both scientific and clinical standards under current regulatory policies and evaluation systems, making its development even more challenging. Especially for the development of 1.2-class new TCM drugs, modern technologies must be used to extract and select effective components from the complex substances of natural medicinal materials to create modern formulations. The development must also be based on traditional Chinese medicine theories while adhering to modern drug evaluation standards through comprehensive preclinical and clinical research. This is particularly difficult for most drug innovations derived from natural products in TCM.
In recent years, Qingfeng Pharmaceutical has adhered to a research-driven development strategy, focusing on the research and development of small molecule drugs and natural medicines, leveraging innovation platforms in cities such as Shanghai, Beijing, Hangzhou, and Ganzhou. In the field of natural medicine innovation, Qingfeng focuses on research into chemical components and pharmacological properties of natural medicines, as well as key control technologies for industrial-scale preparation processes. The company has led 25 national and provincial-level scientific research projects and contributed to the development of 19 new drugs. Qingfeng has applied for 129 invention patents, with 56 patents now granted, gradually establishing its position in the field of natural medicine.
To address the key technical challenges in natural medicine development, such as complex components and low active ingredient content, both of which hinder large-scale industrial separation and purification, Qingfeng Pharmaceutical has established a comprehensive industrial preparation and transformation system centered on industrial chromatography. This system combines natural product extraction, separation, purification, drug formulation, and quality standard research, providing an important bridge for the integration of innovation and industrial chains. The company has applied for 10 invention patents related to the core industrial chromatography technologies, and developed 4 pilot-scale separation and purification processes for innovative drugs, overcoming the challenges of industrial-scale preparation of active ingredients from natural medicines.
Traditional Chinese Medicine (TCM) is a treasure of the Chinese nation and has made significant contributions to human health over thousands of years. In recent years, a series of revised regulations, such as the "Drug Registration Management Measures" and "Traditional Chinese Medicine Registration Classification and Application Requirements," have been released. These guidelines, which align with the characteristics of TCM, fully respect the development rules of traditional medicine, encourage its inheritance and innovation, and have maximized the vitality and potential of TCM.
Under industry policy guidance, Qingfeng Pharmaceutical has established its core principles for the development of innovative TCM drugs. These principles combine traditional knowledge with modern scientific tools and methods, aiming to meet the standards of modern drug formulation while addressing unmet clinical needs. In the face of a complex and ever-changing environment, Qingfeng Pharmaceutical will continue to focus on developing highly original innovative drugs in areas where TCM has a comparative therapeutic advantage. The company is steadily building its "core" competitive edge in TCM innovation, striving to become a leader in the modernization of TCM, and contributing to both the national industry and public well-being.
